Alphaviral vector-transduced dendritic cells are successful therapeutic vaccines against neu-overexpressing tumors in wild-type mice by Moran, Timothy P. et al.
Alphaviral Vector-Transduced Dendritic Cells are Successful
Therapeutic Vaccines against neu-Overexpressing Tumors in
Wild-Type Mice
Timothy P. Moran1,2, Joseph E. Burgents1, Brian Long1, Ivana Ferrer3, Elizabeth M.
Jaffee4, Roland M. Tisch1,3, Robert E. Johnston1,2,3, and Jonathan S. Serody1,3,5
1 Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill,
NC 27599, USA
2 Carolina Vaccine Institute, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
3 Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC
27599, USA
4 Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, The Johns Hopkins University
School of Medicine, Baltimore, Maryland 21231, USA
5 Department of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
Abstract
While dendritic cell (DC) vaccines can protect hosts from tumor challenge, their ability to effectively
inhibit the growth of established tumors remains indeterminate. Previously, we have shown that
human DCs transduced with Venezuelan equine encephalitis virus replicon particles (VRPs) were
potent stimulators of antigen-specific T cells in vitro. Therefore, we investigated the ability of VRP-
transduced DCs (VRP-DCs) to induce therapeutic immunity in vivo against tumors overexpressing
the neu oncoprotein. Transduction of murine DCs with VRPs resulted in high-level transgene
expression, DC maturation and secretion of proinflammatory cytokines. Vaccination with VRP-
transduced DCs (VRP-DCs) expressing a truncated neu oncoprotein induced robust neu-specific
CD8+ T cell and anti-neu IgG responses. Furthermore, a single vaccination with VRP-DCs induced
the regression of large established tumors in wild-type mice. Interestingly, depletion of CD4+, but
not CD8+, T cells completely abrogated inhibition of tumor growth following vaccination. Taken
together, our results demonstrate that VRP-DC vaccines induce potent immunity against established
tumors, and emphasize the importance of the generation of both CD4+ T cell and B cell responses
for efficient tumor inhibition. These findings provide the rationale for future evaluation VRP-DC
vaccines in the clinical setting.
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Vaccination is an attractive approach for treating metastatic cancer, as this strategy would not
only eliminate malignant cells but also prevent recurrent disease through establishment of
immunological memory [1]. Because of their role in initiating adaptive immune responses,
dendritic cells (DCs) expressing tumor-associated antigens are increasingly utilized as
therapeutic cancer vaccines [2]. While DC vaccines have proven highly efficacious in
preventing tumor growth in several preclinical animal models, they have generally failed to
consistently demonstrate objective therapeutic responses in cancer patients [3–8]. One
explanation for this discrepancy may be that animal studies have primarily focused on
prophylactic vaccination, whereas clinical trials typically involve therapeutic vaccination
against established metastatic disease. The microenvironment of established tumors presents
a formidable barrier for antitumor immune responses. Malignant cells can express cell surface
molecules or secrete soluble mediators that directly inhibit NK or T cells [9]. In addition, tumor
stromal cells can produce immunosuppressive cytokines and secrete chemokines that recruit
regulatory cells to the tumor site, resulting in inhibition of tumor immunity [10]. Therefore,
successful vaccination strategies must induce a robust immune response capable of overcoming
immunoregulatory mechanisms present within established tumors.
The limited efficacy of DC vaccines at inducing therapeutic immune responses suggests that
current methods for activation and antigen loading of DCs are suboptimal. Our group has
argued that transduction of DCs with recombinant viral vectors may be an effective strategy
for augmenting vaccine efficacy. Viral vectors can efficiently deliver tumor antigens to DCs
in the context of an immunostimulatory viral infection, resulting in optimal DC activation
[11–14]. Moreover, viral vectors may provide the persistent TLR stimulation deemed necessary
for overcoming Treg-mediated suppression and thus breaking tolerance against tumor antigens
[15]. We previously found that Venezuelan equine encephalitis virus replicon particles (VRP)
could efficiently transduce human DCs, resulting in maturation and secretion of
proinflammatory cytokines [14]. Furthermore, VRP-transduced DCs (VRP-DCs) were
superior to peptide-pulsed DCs at stimulating the expansion of antigen-specific CTL
populations in vitro, arguing that VRP-DCs may be an ideal vaccine for inducing robust tumor
immunity. Based upon these prior results, we sought to examine the efficacy of VRP-DCs as
therapeutic vaccines against the neu oncoprotein, an antigen frequently overexpressed by breast
and ovarian carcinomas.
2. Materials and Methods
2.1 Mice, cell lines and peptides
FVB/N mice (H2q haplotype) were purchased from Jackson Laboratories (Bar Harbor, ME).
Female mice (age 6–12 weeks) were used for all experiments. All animal experiments were
performed in accordance with protocols approved by the University of North Carolina
Institutional Animal Care and Use Committee. NIH-3T3 (American Type Culture Collection),
3T3neu and NT2 cells have been described [16]. RNEU420–429 (PDSLRDLSVF) and
NP118–126 (RPQASGVYM) peptides were purchased from New England Peptide (Gardner,
MA). RNEU420–429 is the immunodominant H2-Dq-restricted epitope from rat neu [17], while
NP118–126 peptide is an H2-Dq-restricted epitope from the lymphocytic choriomeningitis virus
nucleoprotein.
2.2 Generation of VRP-DC vaccines
VRPs encoding GFP (GFP-VRP) or VRPs lacking a functional transgene (null-VRP) have
been described [18]. VRPs encoding the extracellular-transmembrane domains (amino acids
1–697) of rat neu (neuET-VRP) were generated by cloning a neuET cDNA into the pVR21
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replicon plasmid [14]. VRP titer was determined by infection of baby hamster kidney (BHK)
cells [14]. All VRPs were packaged in the wild type (V3000) viral envelope.
DCs were derived from bone marrow progenitor cells in the presence of GM-CSF and IL-4
[19]. On day 7 of culture, immature DCs were harvested and cryopreserved in 90% FBS/10%
DMSO. DCs were stored in liquid nitrogen and used within three months of cryopreservation.
To generate VRP-transduced DC (VRP-DC) vaccines, cryopreserved DCs were thawed at 37°
C and washed twice with RPMI-10 media (RPMI-1640, 10% FBS, 2 mM L-glutamine, 50
μM 2-ME, 100 U/ml penicillin, 100 μg/ml streptomycin sulfate). DCs were plated in 6-well
ultra low attachment plates at 106 cells/ml in RPMI-10 media supplemented with 5 ng/ml GM-
CSF and IL-4, and cultured overnight at 37°C/5% CO2. The next morning, DCs were washed,
suspended in RPMI-1H infection media (RPMI-1640, 1% FBS, 10mM HEPES) and plated at
106 cells/well in 6-well ultra low attachment plates. DCs were infected with VRP at a
multiplicity of infection (MOI) of 10 for 2 hours at 37°C [14]. Infected DCs were washed three
times and suspended in 0.9% sterile saline. Prior to vaccination, female FVB/N mice were
anesthetized by intraperitoneal (i.p.) injection of 1.3 mg ketamine HCl/0.38 mg xylazine. VRP-
DCs (106) were injected subcutaneously (s.c.) in the right axillary mammary gland adjacent to
established tumors.
2.3 Antibodies and flow cytometric analysis
Monoclonal antibodies were purchased from eBioscience (San Diego, CA). The methods for
flow analysis have been described previously [14]. Anti-c-ErbB2/neu (Ab4) monoclonal
antibody was purchased from Calbiochem (San Diego, CA). PE-conjugated H-2Dq/
RNEU420–429 tetramers were synthesized by the NIH Tetramer Facility (Emory University,
Atlanta, GA). For tetramer staining, lymphocytes were incubated with PE-conjugated H-2Dq/
RNEU420–429 tetramers (1:200) for 1 hour at room temperature; anti-CD8, anti-CD3 and anti-
CD62L antibodies were added during the last 15 min of incubation. Cells were washed and
suspended in 0.5% formaldehyde prior to analysis. Quantification of CD8+ T cells specific for
RNEU420–429 was performed by intracellular IFN-γ staining as previously described [20].
2.4 Cytokine secretion assays
Murine DCs were infected with GFP-VRP (MOI =10), washed and plated into 96-well tissue-
culture plates at 105 cells/well in a total volume of 200 μl of media with 5 ng/ml GM-CSF and
IL-4. Analysis of IL-6, TNF-α and IL-10 was performed using the Murine Inflammation
Cytometric Bead Array kit (BD Pharmingen). Analysis of IL-12p70 was performed using the
BD OptEIA™ Mouse IL-12p70 ELISA Set (BD Pharmingen). Analysis of IFNα/β was
determined by a type I interferon (IFN) bioassay [21].
2.5 Detection of serum anti-neu IgG
3T3 or 3T3neu cells were blocked with 20 μg/ml goat IgG (Sigma) for 15 min at 4°C. The cells
were stained with two-fold dilutions of serum from vaccinated FVB/N mice for 1 hour at 4°
C. Cells were washed twice and stained with goat anti-mouse IgG-FITC (Sigma) at a 1:200
dilution for 30 min at 4°C. Cells were washed twice and suspended in 1% formaldehyde. The
median FITC fluorescence intensity (MFI) was measured using a Guava EasyCyte cell analysis
system (Guava Technologies, Hayward, CA). Specific staining of neu was determined by
subtracting the MFI of 3T3 cells from the MFI of 3T3neu cells. The concentration of neu-
specific IgG in sera was calculated using a standard curve generated with Ab4 monoclonal
antibody.
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2.6 Therapeutic vaccination with VRP-DC
For each tumor challenge experiment, a fresh vial from the same lot of cryopreserved NT2
tumor cells was thawed and passaged in vitro for 5–10 days. NT2 cells were harvested, washed,
and suspended in HBSS. FVB/N mice were challenged with 2 × 106 syngeneic NT2 cells s.c.
in the mammary fat pad. Tumors were allowed to establish and grow for 7 days, at which time
mice were vaccinated with VRP-DCs. Tumor area was measured twice weekly with metric
calipers. Mice were sacrificed when tumor area was >200mm2.
2.7 In vivo depletion of lymphocytes
CD4+ or CD8+ T cells were depleted by i.p. injection of 0.5 mg of GK1.5 or 53.6.72 mAb (Bio
Express, West Lebanon, NH), respectively as previously described [16]. Control mice received
i.p. injections of 0.5 mg rat IgG (Sigma). Depletion of specific T cell populations was verified
by flow analysis of splenocytes from treated mice (data not shown).
2.8 Isolation of tumor-infiltrating lymphocytes (TILs)
Tumors from vaccinated mice were excised, disrupted with a razor blade, and incubated under
constant agitation for 1 hour with collagenase A (2.5 mg/ml), DNase I (17 μg/ml) and glass
beads at 37°C. Undigested material was removed using a 100 μm nylon cell strainer. The single-
cell suspension was suspended in 44% Percoll (Sigma), layered on a Lympholyte-M density
gradient (Cedarlane Laboratories, Hornby, ON, Canada), and centrifuged for 30 minutes at
2500 rpm, 25°C. TILs at the Percoll-Lympholyte interface were removed and washed. For
intracellular cytokine staining, TILs were stimulated for 4 hours with PMA (5 ng/ml) and
ionomycin (500 ng/ml), and stained for surface expression of CD4 and CD8. Cells were fixed,
permeabilized, and stained for intracellular expression of IFN-γ.
2.9 Statistical analysis
Statistical differences for costimulatory molecule expression, cytokine expression, and T cell
and antibody responses were calculated by a two-tailed Student’s t test. Differences in survival
were determined by Kaplan-Meier survival analysis. All statistical analyses were performed
with GraphPad Prism® 3.0 software. For all analyses, a P value ≤ 0.05 was considered
significant.
3. Results
3.1 Characterization of VRP-DC vaccines
We initially investigated the ability of VRPs to transduce murine bone marrow-derived DCs
in vitro. Peak expression of GFP in murine DCs occurred 6–12 hours following transduction
with GFP-VRP (data not shown), which was similar to that found using human monocyte-
derived DCs [14]. We next determined if murine DCs could be efficiently transduced with a
VRP encoding neuET. VRP transgene expression peaked at 12 hours post-infection, with 59%
of murine DC expressing high levels of neuET as determined by staining for surface and
intracellular expression of the antigen (Figure 1A). Similar to our previous findings with human
DCs, transgene expression decreased significantly by 36–48 hours post-infection [14]. The
decrease in VRP transgene expression was accompanied by an increase in annexin-V
expression as determined by flow cytometry, indicating that VRP-transduced DCs undergo
accelerated apoptosis (data not shown).
We characterized the ability of VRPs to induce DC activation. VRP-DCs exhibited increased
expression of the costimulatory molecules CD40, CD80 and CD86 in comparison to mock-
infected DCs (Figure 1B). VRP-induced expression of CD40 and CD86 was comparable to
that observed following treatment with LPS, whereas induction of CD80 by VRPs was slightly
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less than that seen with LPS. We also evaluated cytokine secretion by DCs following VRP
infection (Figure 1C). VRP-transduced DCs secreted greater quantities of TNF-α, IL-6 and
IFN-α/β compared to mock-infected DCs. LPS treatment induced more IL-6 secretion than
VRP infection, while neither induced appreciable IL-10 production. Interestingly, VRP
infection of murine DCs did not induce substantial IL-12p70 secretion, which is in contrast to
our previous studies with human DCs [14]. However, VRP infection was a potent inducer of
type I IFN, as VRP-transduced DCs secreted nearly 1000-fold more IFN-α/β than LPS-treated
DCs. DCs treated with VRP that had been inactivated with ultraviolet light were similar to
mock-infected DCs in terms of phenotype and cytokine secretion (data not shown), indicating
that the effects of VRP infection were not due to a contaminant in the VRP preparation. Overall,
VRP infection of murine DCs resulted in high-level transgene expression, phenotypic
maturation, and secretion of proinflammatory cytokines—important characteristics predictive
of a potent DC vaccine.
3.2 VRP-DC vaccines induce potent T cell and antibody responses against neu
We next assessed the immunogenicity of VRP-DC vaccines in vivo. FVB/N mice were
immunized with DCs transduced with neuET-VRP (neuET-DCs), and similarly boosted 14
days later. At seven days post-boost, spleens were harvested and evaluated for neu-specific
CD8+ T cells by intracellular IFN-γ staining. Mice vaccinated with neuET-DCs, but not with
DCs transduced by vector alone (null-DCs), had a significant population of CD8+CD62L− cells
specific for the immunodominant peptide RNEU420–429 (Figure 2A–B).
A shortcoming of traditional peptide-pulsed DC vaccines is their inability to induce antibody
responses. Because humoral immunity is important for controlling the growth of neu-
expressing tumors [22], we evaluated the ability of neuET-DC vaccines to induce neu-specific
antibody responses. neu-specific IgG was readily detectable in the sera from mice vaccinated
with neuET-DCs but not with null-DCs (Figure 3A). Quantification of neu-specific IgG
demonstrated significant levels in mice vaccinated with neuET-DCs, whereas anti-neu IgG
was undetectable in mice vaccinated with null-DCs (Figure 3B). Taken together, these results
indicate that VRP-DC vaccines have the capacity to induce both humoral and cellular immunity
against neu in vivo.
3.3 VRP-DC vaccines induce therapeutic immunity against established tumors
While DC vaccines can frequently protect mice from subsequent tumor challenge or
spontaneous tumor development [12,13], few studies have evaluated their efficacy at inducing
therapeutic immunity in mice with preexisting tumors [11,23,24]. The ability of DC vaccines
to inhibit the growth of established tumors is more relevant for determining clinical efficacy,
as the majority of patients to be vaccinated have existing disease. Therefore, we evaluated the
ability of VRP-DC vaccines to inhibit the growth of established tumors in FVB/N mice. Mice
were challenged with NT2 tumor cells and vaccinated with neuET-DCs seven days later when
tumor size was approximately 50 mm2. A single vaccination with neuET-DCs resulted in
inhibition of tumor growth, and induced regression in the majority of treated mice (Figure 4,
upper panels). Vaccination with neuET-DCs significantly prolonged survival (p=0.005) of
tumor-bearing FVB/N mice when compared to vaccination with null-DCs (Figure 4, lower
panel).
Because effective tumor immunity has been associated with increased lymphocytic infiltration
of tumors [25], we characterized the TILs isolated from the tumor site (Figure 4B). Mice
vaccinated with neuET-DCs had an increased percentage of RNEU420–429-specific CD8+ T
cells as determined by tetramer staining in comparison to mice receiving null-DCs. Mice
vaccinated with neuET-DCs also had an increase in the percentages of IFN-γ+ CD8+ and
CD4+ T cells at the tumor site, indicating a possible mechanism for tumor clearance.
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3.4 CD4+ T cells are critical for inhibition of established tumors following VRP-DC vaccination
The increased numbers of neu-specific CD8+ TIL in mice vaccinated with neuET-DCs
suggested that CD8+ T lymphocytes may be the primary effector cells responsible for
controlling the growth of established tumors. To more specifically evaluate the role of different
T cell populations in mediating inhibition of tumor growth, we depleted mice of either CD4+
or CD8+ T cells prior to vaccination (Figure 5). Treatment with GK1.5 or 53.6.72 monoclonal
antibodies resulted in >99% depletion of splenic CD4+ or CD8+ T cells, respectively (data not
shown). Interestingly, tumor immunity was only partially dependent upon CD8+ T cells, as
62.5% of CD8-depleted mice survived to day 60 post-tumor challenge. Conversely, we found
that CD4+ T cells were crucial for effective tumor immunity, as all CD4-depleted mice
experienced rapid tumor growth and had to be euthanized within four weeks of tumor-challenge
(Figure 5). Taken together, the presence of tumor-specific CD8+ T cells does not appear to be
an absolute requirement in our vaccination model, whereas CD4+ T cells are essential for
inhibition of tumor growth.
4. Discussion
The optimal DC vaccine would not only present significant quantities of antigen, thus allowing
optimal activation of lymphocytes, but would also produce immune-enhancing cytokines
necessary for T cell differentiation into functional effector cells [2]. Our previous studies with
human DCs demonstrated that VRP transduction of DCs resulted in cellular activation,
secretion of proinflammatory cytokines, and efficient stimulation of antigen-specific T cells.
Based on these findings, we sought to determine if VRP-DCs expressing a relevant tumor
antigen could induce effective therapeutic immunity against established tumors.
VRP-transduced DCs have many putative characteristics of potent DC vaccines, namely high-
level transgene expression, upregulation of costimulatory molecules and secretion of
proinflammatory cytokines. VRPs could efficiently transduce >50% of DCs at an MOI of 10.
In comparison, infection of DCs with adenoviral vectors at an MOI of 300 resulted in only
39.5% transduction efficiency [13]. While neu protein levels were high at 12 hours post-
infection, transgene expression declined significantly between 36–48 hours post-infection,
likely due to VRP-induced apoptosis. It is possible that vector-induced apoptosis could limit
the therapeutic application of VRP-DCs, although our data suggests that the lifespan of VRP-
DCs is sufficient for activation of B and T cells. It is conceivable that VRP-mediated apoptosis
may actually facilitate T cell activation, as transduced DCs undergoing apoptosis can augment
immune responses via cross-presentation of DC-associated antigens by endogenous APCs
[26]. Regardless of the effects of VRP-induced apoptosis on T cell activation, it is clear that
the limited lifespan of VRP- DCs did not preclude the development of anti-neu responses and
therapeutic tumor immunity in our model (Figures 2–4).
VRP transduction of DCs resulted in phenotypic maturation and secretion of the
proinflammatory cytokines TNF-α and IL-6, but not the immunosuppressive cytokine IL-10.
VRP-infected DCs also secreted large amounts of type I interferons, which can augment tumor
immunity by activating NK cell activity [27], enhancing cross-presentation of antigen to
CD8+ T cells [28], and inducing clonal expansion of antigen-specific CD4+ and CD8+ T cells
[29,30]. While high-level secretion of type I interferons is typically associated with
plasmacytoid DCs, myeloid DCs can become robust producers of IFN-α/β following direct
infection with RNA viruses [31]. In contrast to our studies with human DCs, VRP transduction
of murine DCs did not induce significant secretion of IL-12p70. IL-12p70 promotes the
production of IFN-γ and development of TH1 immune responses [32], which are often deemed
necessary for effective tumor immunity. Nevertheless, previous studies have shown that IL-12
production by DC vaccines is not necessary for induction of antigen-specific CTL responses
in vivo [33], which is consistent with our observations that VRP-DC vaccines could induce
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neu-specific CD8+ T cells. It is possible that cytokines such as IFN-α may substitute for IL-12
in providing the signals necessary for T cell proliferation and survival following antigen-
specific activation [34]. Although IL-12 production by VRP-DC vaccines does not appear to
be required for activation of CD8+ T cells, IL-12p70 secretion could conceivably be enhanced
either by codelivery of IL-12-expressing VRPs or by treatment with CD40L [12,35].
VRP-DC vaccines not only induced neu-specific CD8+ T cells, but also stimulated antibody
responses against neu in wild-type mice—an important advantage for this vaccine strategy.
While most studies judge the effectiveness of DC vaccines solely on their ability to stimulate
CD8+ T cells, both humoral and cell-mediated immunity are necessary for complete clearance
of neu-overexpressing tumor cells [22].
Because the majority of breast cancer patients present with long-standing disease with multiple
metastases, successful vaccine platforms must be capable of inducing robust immune responses
against sizeable solid tumors. Established tumors are often resistant to both immunological
and pharmacological therapies. Not only do stromal cells act as a direct barrier to cellular and
humoral components of the immune system, but they can also secrete anti-inflammatory
mediators that dampen immune responses within the tumor environment [10]. In the current
study, we observed that therapeutic vaccination with VRP-DCs significantly inhibited the
growth of established tumors, and even induced regression in the majority of animals. Tumor
regression was associated with a significant infiltrate of both IFN-γ-producing CD4+ and
CD8+ T cells at the tumor site. IFN-γ is known to have potent anti-tumor activity through direct
action upon malignant cells and indirectly through effects on tumor stromal cells [36]; therefore
the induction of IFN-γ-producing TIL may be essential for the efficacy of VRP-DC vaccines.
The role of IFN-γ and other cytokines in mediating immunity against established tumors in our
vaccination model is currently being evaluated.
Interestingly, we found that CD4+ T cells were more important than CD8+ T cells for tumor
inhibition following VRP-DC vaccination. CD4+ T cells are likely necessary for augmenting
the expansion and activity of tumor-specific CD8+ T cells and the development of anti-neu
antibody responses. A similar dependency of neu-specific immunity upon CD4+ T cells has
been found in other studies. The efficacy of a vaccine composed of DCs transduced with an
adenoviral vector encoding neuET required the presence of CD4+ but not CD8+ T cells in neu-
T transgenic BALB/c mice [13]. CD4+ T cells were necessary for clearance of tumors in FVB/
N mice vaccinated with irradiated 3T3neu cells expressing GM-CSF, although CD8+ T cells
also had an important role in this model [22]. Taken together, these studies suggest that cancer
vaccines that activate both CD4+ and CD8+ T cells are likely to be more successful than those
aimed solely at stimulating CTL responses.
While tumor and stromal cells can directly inhibit antitumor responses, suppression of tumor
immunity by hematopeoitically-derived regulatory cells is also important for tumor immune
evasion. Notably, CD4+CD25+ regulatory T cells and myeloid suppressor cells can be recruited
to the tumor site, where they mediate tolerance against tumor antigens and dampen tumoricidal
responses [37]. Studies have demonstrated that tolerance against tumor antigens can be
overcome through activation of TLR signaling by viral vectors, which may explain the efficacy
of VRP-DCs [15]. However, while VRP-DCs can inhibit the growth of established tumors in
FVB/N mice, preliminary studies have failed to demonstrate tumor regression in transgenic
mice tolerant to the neu antigen (T. Moran, R. Johnston, and J. Serody, unpublished
observations). These preliminary findings suggest that viral activation of DCs alone may not
be sufficient for effective tumor immunity under conditions of tolerance. The mechanisms
responsible for inhibiting tumor immunity in tolerant animals are currently being explored in
our laboratory.
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In summary, VRPs encoding a tumor antigen could efficiently transduce murine DCs, resulting
in maturation and proinflammatory cytokine production. VRP-DC vaccines were highly
immunogenic in vivo, and were capable of inducing both cellular and humoral immunity against
neu. Most importantly, a single vaccination with VRP-DCs expressing neuET induced
regression of bulky tumors, demonstrating that VRP-transduced DCs are potent vaccines with
the capacity to induce effective therapeutic immunity against established tumors in wild-type
mice. Therefore, VRP-transduced DCs may prove to be an optimal vaccine for immunotherapy
of metastatic disease in the clinical setting.
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Figure 1. VRP transduction results in high-level transgene expression and DC activation
A. DCs were transduced with neuET-VRP (MOI = 10) and analyzed 12 hours later for
expression of neuET by FACS. B. DCs were mock-infected (open bars), infected with GFP-
VRP (solid bars), or treated with 100 ng/ml LPS (hatched bars). 24 hours later, DCs were
stained for CD40, CD80, and CD86. Expression of costimulatory molecules on VRP-infected
DCs was determined by gating on GFP+ DCs. Bars represent the mean +/− SEM (n = 4 per
group). One of four similar experiments is depicted. C. DCs were mock-infected (open
squares), infected with GFP-VRP (closed circles), or treated with 100 ng/ml LPS (open
triangles). Cytokine levels were evaluated at the indicated times post-infection as described in
Materials and Methods. *p<0.001 v. mock-DCs, Student’s t test.
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Figure 2. Vaccination with VRP-DCs expressing neuET induces neu-specific CD8+ T cells
FVB/N mice (n = 6 mice per group) were vaccinated with 106 null- or neuET-DCs, and
similarly boosted two weeks later. At seven days post-boost, splenocytes were isolated and
stimulated with either RNEU420–429 peptide or irrelevant NP118–126 peptide and assayed for
intracellular IFN-γ expression. A. Representative staining of gated CD3+CD8+ T cells from
vaccinated mice. B. The frequency of RNEU420–429-specific CD8+ T cells was determined by
subtracting the frequency of NP118–126 specific T cells. Bars represent the mean +/− SEM.
Data is representative of two experiments.
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Figure 3. VRP-DC vaccines stimulate robust serum levels of neu-specific IgG
FVB/N mice (n = 6 mice per group) were vaccinated with 106 null- or neuET-DCs, and
similarly boosted two weeks later. At seven days post-boost, sera was harvested and used to
stain 3T3 cells or 3T3neu cells, followed by staining with goat anti-mouse IgG-FITC. A.
Representative staining of 3T3 cells (shaded histogram) or 3T3neu cells (heavy line) with sera
from mice vaccinated with either null-DCs or neuET-DCs. B. Quantification of serum anti-
neu IgG in vaccinated mice. Bars represent the mean +/− SEM. *p<0.001, Student’s t test.
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Figure 4. Therapeutic VRP-DC vaccination of tumor-bearing FVB/N mice inhibits tumor growth
and induces tumor-infiltrating effector T cells
A. FVB/N mice (n = 6 mice per group) were challenged with 2 × 106 NT2 tumor cells on day
0. Seven days later, mice received a single vaccination of 106 null- or neuET-DCs (solid arrow)
and were evaluated for tumor growth (upper figures) and survival (lower figure). Mice
vaccinated with neuET-DC demonstrated a significantly prolonged survival (p = 0.005,
Kaplan-Meier survival analysis). One of two similar experiments is shown. B. TIL were
isolated at 21 days post-vaccination. neu-specific CD8+ T cells were determined by staining
with H2-Dq/RNEU420–429 tetramers. For assessment of IFN-γ production, TIL were stimulated
for 4 h with PMA/ionomycin prior to intracellular IFN-γ staining.
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Figure 5. CD4+ T cells are critical for inhibition of tumor growth following VRP-DC vaccination
FVB/N mice (8–10 mice per group) were depleted of CD8 or CD4 T cells by treatment with
53.6.72 or GK1.5 mAb, respectively. Control mice received rat IgG. T cell-depleted mice were
challenged with 2 × 106 NT2 cells and vaccinated with 106 neuET-DC seven days later (solid
arrow). T cell depletions were maintained by injection of antibody every 4–5 days during
monitoring of survival. Cumulative data from two experiments is shown. Survival of mice
receiving rat IgG was significantly increased when compared to GK1.5-treated mice or
53.6.72-treated mice (p < 0.001 for both groups, Kaplan-Meier survival analysis).
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